Study M657
Study name | Sun Y 2020 |
Title | The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine |
Overall design | The aim of this study was to investigate differential associations between the antidepressant treatment outcome to escitalopram versus desvenlafaxine with the pre-treatment and post-treatment-changes in serotonin and kynurenine pathway metabolite levels. The levels of serotonin and of kynurenine pathway metabolites were measured in plasma using liquid chromatography-mass spectrometry (LC-MS) in currently depressed patients with MDD (MDD group, n = 161) at baseline and after 8 weeks of treatment with either escitalopram (escitalopram-treated MDD group, n = 78) or desvenlafaxine (desvenlafaxine-treated MDD group, n = 83), and healthy controls (control group, n = 28). Treatment response was defined conventionally by a reduction of at least 50% in the Hamilton Depression Rating Scale 21 item (HAMD-21) total score from baseline; remission was defined by reaching a post-treatment HAMD-21 score <= 7. |
Study Type | Type1; Type2; Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-V diagnosed MDD, HAMD-21 >= 20 |
Sample size | 189 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; LC-MS: API 5500 QTRAP detector; |
PMID | |
DOI | |
Citation | Sun Y, Drevets W, Turecki G, et al. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine. Brain Behav Immun. 2020;87:404-412. |
Metabolite | Serotonin; Kynurenine/Tryptophan ratio; |
